Trastuzumab works by binding to the HER2 receptor on the surface of cancer cells. This binding inhibits cell proliferation and induces antibody-dependent cellular cytotoxicity (ADCC), leading to the destruction of the cancer cells. It also interferes with the HER2 receptor's ability to send growth signals, thereby slowing down or stopping the growth of cancer.
